Compare American Superconductor Corporation (AMSC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Zimmer Biomet Holdings Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.67B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 10.2× American Superconductor Corporation's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | ZBH | |
|---|---|---|
Market Cap | $1.74B | $17.67B |
Sector | Technology | Health |
52-Week High | $66.68 | $107.71 |
52-Week Low | $25.95 | $79.58 |
Enterprise Value | $1.61B | $24.72B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
Zimmer Biomet (ZBH) trades at $91.34, up 2.36% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong profitability with a 70.03% gross margin and has beaten earnings estimates for three consecutive quarters. Recent developments include a $140M acquisition and plans to hire 500 employees in India, signaling growth initiatives.
Outlook is cautiously optimistic with a consensus price target of $98.00, though rising debt levels and competitive pressures pose risks. The stock offers steady dividend income and share repurchases, but investors should weigh execution risks against solid cash flow generation and market positioning in medical devices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
